New combo therapy targets Hard-to-Treat breast cancer
NCT ID NCT05095207
First seen Apr 14, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study tests two drugs, abemaciclib and bicalutamide, together in people with a certain type of advanced breast cancer (androgen receptor-positive, HER2-negative) that has spread. The goal is to find the best dose and see if the combination is safe and can control the disease. About 42 women will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dubin breast Center
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai - West
RECRUITINGNew York, New York, 10019, United States
-
Mount Sinai Beth Israel
RECRUITINGNew York, New York, 10003, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib and bicalutamide
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of metastatic breast cancer that is harder to treat.
What could go wrong
This is an early-phase trial with only 42 participants, so it may not show enough benefit or could have unexpected side effects. The combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.